Company Overview - Catalyst Pharmaceuticals is a U.S.-based biotechnology company focused on developing and commercializing therapies for rare neuromuscular and neurological diseases [6] - The company has a market capitalization of $2.86 billion, with a revenue of $578.20 million and a net income of $217.56 million for the trailing twelve months (TTM) [4] - Catalyst's stock has experienced a 1-year price change of 11.74% as of December 31, 2025 [4] Recent Transaction - Jeffrey Del Carmen, Chief Commercial Officer, exercised and sold 10,983 shares of common stock on November 26, 2025, for approximately $256,200 [1][2] - This transaction involved converting stock options into cash proceeds, significantly reducing Del Carmen's direct equity holdings by approximately 73.49%, leaving him with 3,962 shares post-transaction [7] - The transaction value was based on a weighted average purchase price of $23.33 per share [2] Financial Performance - Catalyst Pharmaceuticals reported strong third-quarter results with revenues of $148.4 million, reflecting a year-over-year increase of 17.4% [10] - The company raised its full-year 2025 revenue guidance, indicating consistent profitable growth [10] - At the time of the sale, Catalyst's stock was trading between $19.05 and $26.58, with analysts raising price targets to a consensus estimate of around $34 per share [11] Product Portfolio - Key products include Firdapse for Lambert-Eaton myasthenic syndrome (LEMS) and Ruzurgi for pediatric LEMS, with ongoing pipeline development targeting additional rare neuromuscular and neurological indications [8] - The company operates a commercial-stage biopharmaceutical model, generating revenue primarily from the sale of approved therapies for rare diseases in the United States [8]

Group 1 - Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is considered a cheap healthcare stock with a consensus Buy rating from all seven analysts covering it, indicating a potential upside of 48.75% from its current price of $35 [1] - The company is focused on advancing education in the oncology space and accelerating organic growth by targeting patients at various stages of the diagnostic journey, despite competition in the epilepsy market [3] - Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company based in Florida, founded in 2002, and offers treatments such as Firdapse, Fycompa, Ruzurgi, and AGAMREE for life-threatening diseases [4] Group 2 - On November 26, the Chief Commercial Officer of Catalyst Pharmaceuticals, Jeffrey Del Carmen, sold 10,983 shares of common stock for approximately $256,244, leaving him with 3,962 shares [2]